Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer

Share :
Published: 9 Jul 2024
Views: 16
Dr Giovanni Randon - The National Cancer Institute of Milan, Milano, Italy

Dr Giovanni Randon speaks to ecancer about his ARMANI phase III trial.

This study evaluated the efficacy of switch maintenance therapy in patients with HER2-negative advanced gastric or gastroesophageal junction cancer who did not progress after 3 months of oxaliplatin-based chemotherapy.

Patients were randomised to receive either ramucirumab plus paclitaxel or continued CAPOX/FOLFOX followed by fluoropyrimidine monotherapy.

The primary endpoint was progression-free survival (PFS).

Results showed a significant improvement in median PFS and overall survival (OS) with ramucirumab plus paclitaxel compared to the CAPOX/FOLFOX group.

The benefits were consistent across various clinical and molecular subgroups, including those with low PD-L1 expression.